Browsing Tag

Nasdaq:ACIU

AC Immune Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s…

James Pereira Oct 4, 2022

Interim analysis expected around year-end 2022, informing Phase 2 startTrial progressing with regulatory clearances in…
Read More...

AC Immune’s Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA…

James Pereira May 9, 2022

First study of an anti-Abeta vaccine in people living with Down syndrome (DS) Immune response and Alzheimer’s disease…
Read More...

AC Immune Announces Late-Breaker Presentation by Genentech at CTAD on Phase 2 Lauriet Study of…

James Pereira Nov 10, 2021

Analysis of the broader mITT population is consistent with the previously reported success in meeting one of the two…
Read More...